Radames Sierra Zorita
Rheumatology · San Juan, PRNPI 1669457875
Payments from drug & device makers
Across 1,063 payments — averaging $402.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$196K
- AbbVie$70K
- Novartis$55K
- Radius Health, Inc.$32K
- E.r. Squibb & Sons, L.L.C.$10K
- Bristol Myers Squibb$10K
- plus $55K from 24 others
What the payments were for
- Consulting fees$62,05515%
- Speaking & faculty fees$293,85269%
- Travel & lodging$37,5079%
- Food & beverage$33,7798%
- Education$5070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 301 | $195,949 |
| AbbVie | 195 | $69,902 |
| Novartis | 150 | $54,960 |
| Radius Health, Inc. | 50 | $31,823 |
| E.r. Squibb & Sons, L.L.C. | 55 | $10,228 |
| Bristol Myers Squibb | 25 | $10,093 |
| UCB, Inc. | 33 | $9,021 |
| Pfizer | 7 | $8,152 |
| Sanofi | 18 | $7,610 |
| Merck | 14 | $6,442 |
| Lilly USA, LLC | 4 | $6,203 |
| Regeneron Healthcare Solutions, Inc. | 12 | $3,944 |
| Johnson & Johnson(2 entities) | 48 | $3,886 |
| Pfizer Pharmaceuticals LLC | 7 | $2,940 |
| PBG Puerto Rico LLC | 37 | $1,352 |
| Mallinckrodt Hospital Products Inc. | 23 | $1,098 |
| AstraZeneca(2 entities) | 21 | $1,094 |
| Ferring Pharmaceuticals Inc. | 2 | $1,008 |
| GSK | 20 | $563 |
| Eli Lilly Export S.A. Puerto Rico Branch | 16 | $419 |
| Genentech, Inc. | 3 | $263 |
| Boehringer Ingelheim | 8 | $186 |
| Sanofi-aventis U.S. LLC | 3 | $123 |
| Janssen Scientific Affairs, LLC | 1 | $121 |
| Hikma Pharmaceuticals USA | 4 | $87 |
| Organon | 1 | $62 |
| Actelion Pharmaceuticals US, Inc. | 1 | $55 |
| ANI Pharmaceuticals, Inc. | 2 | $50 |
| Sobi, Inc | 1 | $45 |
| Mallinckrodt Enterprises LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$427,700 in reported general payments places this provider in the 95th percentile of 88 rheumatology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 275 | $1,943,155 |
| RinvoqUpadacitinib | 198 | $1,281,440 |
| Enbrel SureclickEtanercept | 150 | $1,117,828 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 73 | $540,638 |
| Xeljanz XrTofacitinib Citrate | 84 | $489,225 |
| KevzaraSarilumab | 111 | $482,436 |
| SimponiGolimumab | 71 | $428,473 |
| Cosentyx Unoready PenSecukinumab | 49 | $396,187 |
| Orencia ClickjectAbatacept | 62 | $353,105 |
| ProliaDenosumab | 128 | $223,975 |
| OtezlaApremilast | 34 | $164,765 |
| Humira(Cf)Adalimumab | 19 | $132,013 |
| Actemra ActpenTocilizumab | 28 | $131,718 |
| Cimzia (2 Pack)Certolizumab Pegol | 21 | $118,384 |
| OrenciaAbatacept/Maltose | 15 | $82,847 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf), Synthroid | $69,902 | $1,414,429233 claims |
| SanofiKevzara | $7,610 | $482,436111 claims |
| Johnson & JohnsonSimponi | $3,886 | $428,47371 claims |
| AmgenProlia, Otezla | $195,949 | $388,740162 claims |
| UCB, Inc.Cimzia (2 Pack) | $9,021 | $118,38421 claims |
| Lilly USA, LLCForteo, Olumiant | $6,203 | $102,52128 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $10,228 | $82,84715 claims |
| Radius Health, Inc.Tymlos | $31,823 | $79,90330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 88 rheumatology providers in Puerto Rico.
Other rheumatology in San Juan
- Carlos PantojasSan Juan$3.2M
- Oscar Soto RaicesSan Juan$3.1M
- Paloma AlejandroSan Juan$347K
- Maria Chirino-SociasSan Juan$296K
- Yvonne FontSan Juan$193K
- Jose Ramirez VazquezSan Juan$171K
- Grissel RiosSan Juan$119K
- Irma Vazquez-SanabriaSan Juan$11K
- Valerie Marrero PereaSan Juan$10K
- Ariana Gonzalez-MelendezSan Juan$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.